Published: June 2020
Empowered by technical developments in the field of biotechnology and the market opportunity associated with regenerative medicine, a number of research groups across the world are presently developing innovative ways to reprogram cells
Roots Analysis has announced the addition of “Cell Reprogramming (iPSC Generation) / Direct Reprogramming Services and Products Market, 2020-2030” report to its list of offerings.
Legacy challenges concerning the development and use of cell therapies include complex production process, scarcity of healthy cell donors, and concerns associated with donor-recipient haplotype mismatch. Moreover, there are still several ethical barriers when it comes to using human stem cells for research purposes. The concept of cell reprogramming offers the means to bypass almost all of the aforementioned issues and develop safe and effective cell-based therapeutic interventions.
To order this 190+ page report, which features 70+ figures and 90+ tables, please visit this link
More than 30 companies claim to offer cell reprogramming services and products
Of the involved players, close to 70% are small firms (having less than 50 employees). More than 70% of companies were involved in providing iPSC generation services, followed by those offering direct reprogramming services (30%). It is worth mentioning that majority of stakeholders (14) claim to be using episomal reprogramming for generating iPSCs; other popular cell reprograming approaches include Sendai virus and mRNA-based technologies.
North America is a key services hub for cell reprogramming
More than 55% of companies engaged in the cell reprogramming, are headquartered in North America. This is followed players based in Europe (45%); key hubs within Europe include (in decreasing order of number of companies) the UK, Germany, Denmark, Switzerland, France, Portugal and Sweden.
Partnership activity has grown at an annualized rate of nearly 10%, between 2016 and 2019
In fact, more than 50% of the reported deals were established post 2017, with the maximum partnership activity observed in 2018. Majority of the agreements captured in the report were focused on research and development, research and licensing and product development.
Presently, the majority share of service revenues is generated from projects involving episomal reprogramming technologies
In 2030, episomal reprogramming focused projects are anticipated to contribute to over 40% of the overall share; it is expected to be followed by revenues from projects involving Sendai virus-based reprogramming (30%) and mRNA (25%). Further, the services market opportunity for other reprogramming technologies is estimated to grow at an annualized rate of 7%, till 2030.
To request a sample copy / brochure of this report, please visit this link
The USD 2.32 billion (by 2030) financial opportunity within the cell reprogramming services and products market has been analyzed across the following segments:
The report features inputs from eminent industry stakeholders, according to whom, the adoption of cell reprogramming services and technologies is likely to increase in the foreseen future owing to various applications of this technique in personalized stem cell therapy, regenerative medicine and stem cell research. The report includes detailed transcripts of discussions held with the following experts:
The research includes detailed profiles of key players (listed below) that offer cell reprogramming services and products; each profile features an overview of the company, its financial information (if available), recent developments and an informed future outlook.
For additional details, please visit
or email email@example.com
You may also be interested in the following titles:
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry